^
Association details:
| Biomarker: | AR underexpression |
|---|---|
| Cancer: | Triple Negative Breast Cancer |
| Drug: | carboplatin (Tubulin polymerization promoter) + paclitaxel (Bcl2 inhibitor, Tubulin polymerization promoter) |
| Direction: | Resistant |
Evidence:
Source:
Title:
A prospective phase II clinical trial identifying the optimal regimen for carboplatin plus standard backbone of anthracycline and taxane-based chemotherapy in triple negative breast cancer
Published date:
02/01/2022
Excerpt:
90 TNBC patients were enrolled onto our trial. The most successful version placed the carboplatin on the second and final paclitaxel treatment with liberal hematological parameters....Reduction in protein levels of androgen receptor and PD-L1 were found to be potential indicators of patient relapse....Early data indicates reduced protein levels of androgen receptor and PD-L1 as indicators of response to treatment.
DOI:
10.1007/s12032-021-01637-0
